KLK3 and prostate cancer: Our previous in vivo studies using prostate cancer xenograft mouse models implanted with C4-2B prostate cancer cells showed that NMI is targeted specifically to the tumor, reducing the MAO A catalytic activity, tumor growth, and reducing the prostate-specific antigen (PSA), a biomarker for prostate cancer [5].